Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns (Q36983284)

17 August 2017

Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns (English)

1 reference

17 August 2017

0 references

1

Paul Hodgkins

1 reference

17 August 2017

7

Monica Shaw

1 reference

17 August 2017

2

Juliana Setyawan

1 reference

17 August 2017

3

Debanjali Mitra

1 reference

17 August 2017

Keith Davis

4

1 reference

17 August 2017

Javier Quintero

series ordinal

5

1 reference

17 August 2017

Moshe Fridman

series ordinal

6

1 reference

17 August 2017

Valerie Harpin

series ordinal

8

1 reference

17 August 2017

26 February 2013

1 reference

European Journal of Pediatrics

17 August 2017

1 reference

17 August 2017

172

1 reference

17 August 2017

7

1 reference

17 August 2017

895-906

1 reference

Creative Commons Attribution 2.0 Generic

17 August 2017

start time

26 February 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

The effect of ADHD on the life of an individual, their family, and community from preschool to adult life

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

The Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Pediatric Patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Long-term prognosis in attention-deficit/hyperactivity disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

The Hyperactive Child in Elementary School: A 5 Year, Controlled, Followup

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Why do children with ADHD discontinue their medication?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

ADHD medication use, adherence, persistence and cost among Texas Medicaid children

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

European clinical guidelines for hyperkinetic disorder -- first upgrade

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Attention-deficit/hyperactivity disorder: increased costs for patients and their families

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Attention-deficit/hyperactivity disorder: a life-span perspective.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3701791

Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23440479

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Variations in compliance among hypertensive patients by drug class: implications for health care costs

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23440479

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00431-013-1969-8

1 reference

release_6fsgclvoafdfppgg5riljx7pbm

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6fsgclvoafdfppgg5riljx7pbm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

17 August 2017

PubMed publication ID

23440479

1 reference